AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of “Moderate Buy” by Analysts

AngioDynamics, Inc. (NASDAQ:ANGO) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $18.6667.

A number of research analysts have recently commented on the stock. Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Canaccord Genuity Group lowered their price target on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a report on Monday, April 6th. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th.

AngioDynamics Price Performance

NASDAQ ANGO traded down $0.02 on Tuesday, reaching $12.96. The company had a trading volume of 105,385 shares, compared to its average volume of 468,282. AngioDynamics has a 1 year low of $8.36 and a 1 year high of $13.99. The firm has a 50-day moving average of $11.84 and a 200-day moving average of $11.34. The firm has a market capitalization of $535.34 million, a PE ratio of -17.27 and a beta of 0.34.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC grew its stake in AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of AngioDynamics in the 4th quarter valued at approximately $27,000. State of Wyoming purchased a new position in shares of AngioDynamics during the 2nd quarter valued at approximately $31,000. Russell Investments Group Ltd. boosted its stake in shares of AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 3,213 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 4,268 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.